Overexpression of Lymphocyte Activation Gene-3 Inhibits Regulatory T Cell Responses in Osteoarthritis

被引:19
作者
Xia, Junjie [1 ]
Ni, Zhiming [1 ]
Wang, Jian [2 ]
Zhu, Shu [1 ]
Ye, Hong [1 ]
机构
[1] PLA, Dept Orthoped, Hosp 117, 14 Lingyin Rd, Hangzhou 310013, Zhejiang, Peoples R China
[2] Pudong New Area Peoples Hosp, Dept Orthoped, Shanghai, Peoples R China
关键词
IL-10; LAG-3; regulatory T cell; osteoarthritis; EFFECTOR FUNCTION; SELF-TOLERANCE; IN-VITRO; LAG-3; EXPRESSION; DISEASE; CANCER; INFLAMMATION; RECEPTORS; PROTEIN;
D O I
10.1089/dna.2017.3771
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Lymphocyte activation gene-3 (LAG-3) is a CD4 homologue expressed on the surface of activated conventional T cells and regulatory T (Treg) cells. In conventional T cells, LAG-3 acts as an inhibitory receptor of T cell inflammation. However, the role of LAG-3 in Treg cells remains controversial. In this study, we investigated the effect of LAG-3 on Tregs in osteoarthritis (OA). We observed that the proportion of LAG-3-expressing cells in CD4(+)CD25(+/high) T cells and Foxp3(+)CD4(+)CD25(+/high) T cells were significantly upregulated in OA patients. The level of LAG-3-to-Foxp3 ratio was further increased in synovial fluid. Several aspects of Treg responses in LAG-3(+) and LAG-3(-) Treg cells were then examined. First, LAG-3(+) Treg cells demonstrated significantly lower proliferation than LAG-3(-) Treg cells. Second, the increase in interleukin (IL)-10 and transforming growth factor (TGF)- expression was significantly lower in LAG-3(+) Treg cells than that in LAG-3(-) Treg cells. Third, LAG-3(+) Treg cells were less capable of inhibiting the proliferation of CD4(+)CD25(-) conventional T cells than LAG-3(-) Treg cells. This study suggests that Treg cells in OA may be enriched with a LAG-3-expressing population that exhibits functional impairment, which limits their capacity in suppressing inflammation.
引用
收藏
页码:862 / 869
页数:8
相关论文
共 50 条
[41]   TRPC3 Overexpression Promotes the Progression of Inflammation-Induced Preterm Labor and Inhibits T Cell Activation [J].
Jing, Chen ;
Dongming, Zheng ;
Hong, Cui ;
Quan, Na ;
Sishi, Liu ;
Caixia, Liu .
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2018, 45 (01) :378-388
[42]   Molecular cloning of bovine lymphocyte activation gene-3 and its expression characteristics in bovine leukemia virus-infected cattle [J].
Shirai, Tatsuya ;
Konnai, Satoru ;
Ikebuchi, Ryoyo ;
Okagawa, Tomohiro ;
Suzuki, Saori ;
Sunden, Yuji ;
Onuma, Misao ;
Murata, Shiro ;
Ohashi, Kazuhiko .
VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, 2011, 144 (3-4) :462-467
[43]   Lymphocyte activation gene 3 and coronary artery disease [J].
Golden, Diana ;
Kolmakova, Antonina ;
Sura, Sunitha ;
Vella, Anthony T. ;
Manichaikul, Ani ;
Wang, Xin-Qun ;
Bielinski, Suzette J. ;
Taylor, Kent D. ;
Chen, Yii-Der Ida ;
Rich, Stephen S. ;
Rodriguez, Annabelle .
JCI INSIGHT, 2016, 1 (17)
[44]   Lymphocyte-Activation Gene-3 Expression and Prognostic Value in Neoadjuvant-Treated Triple-Negative Breast Cancer [J].
Wang, Yunxuan ;
Dong, Tieying ;
Xuan, Qijia ;
Zhao, Hong ;
Qin, Ling ;
Zhang, Qingyuan .
JOURNAL OF BREAST CANCER, 2018, 21 (02) :124-133
[45]   Therapeutic approaches to allergy and autoimmunity based on FoxP3+ regulatory T-cell activation and expansion [J].
Miyara, Makoto ;
Wing, Kajsa ;
Sakaguchi, Shimon .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2009, 123 (04) :749-755
[46]   Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3 [J].
Mao, Xiaobo ;
Ou, Michael Tianhao ;
Karuppagounder, Senthilkumar S. ;
Kam, Tae-In ;
Yin, Xiling ;
Xiong, Yulan ;
Ge, Preston ;
Umanah, George Essien ;
Brahmachari, Saurav ;
Shin, Joo-Ho ;
Kang, Ho Chul ;
Zhang, Jianmin ;
Xu, Jinchong ;
Chen, Rong ;
Park, Hyejin ;
Andrabi, Shaida A. ;
Kang, Sung Ung ;
Goncalves, Rafaella Araujo ;
Liang, Yu ;
Zhang, Shu ;
Qi, Chen ;
Lam, Sharon ;
Keiler, James A. ;
Tyson, Joel ;
Kim, Donghoon ;
Panicker, Nikhil ;
Yun, Seung Pil ;
Workman, Creg J. ;
Vignali, Dario A. A. ;
Dawson, Valina L. ;
Ko, Han Seok ;
Dawso, Ted M. .
SCIENCE, 2016, 353 (6307)
[47]   Lymphocyte-activation gene 3 (LAG-3) as a promising immune checkpoint in cancer immunotherapy: From biology to the clinic [J].
Alqurashi, Yaser E. .
PATHOLOGY RESEARCH AND PRACTICE, 2024, 254
[48]   Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma [J].
Hamid, Omid ;
Lewis, Karl D. ;
Weise, Amy ;
McKean, Meredith ;
Papadopoulos, Kyriakos P. ;
Crown, John ;
Kim, Tae Min ;
Lee, Dae Ho ;
Thomas, Sajeve S. ;
Mehnert, Janice ;
Kaczmar, John ;
Lakhani, Nehal J. ;
Kim, Kevin B. ;
Middleton, Mark R. ;
Rabinowits, Guilherme ;
Spira, Alexander I. ;
Yushak, Melinda ;
Mehmi, Inderjit ;
Fang, Fang ;
Chen, Shuquan ;
Mani, Jayakumar ;
Jankovic, Vladimir ;
Wang, Fang ;
Fiaschi, Nathalie ;
Brennan, Laura ;
Paccaly, Anne ;
Masinde, Sheila ;
Salvati, Mark ;
Fury, Matthew G. ;
Kroog, Glenn ;
Lowy, Israel ;
Gullo, Giuseppe .
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (24) :2928-2938
[49]   Unlocking therapeutic potential: Targeting lymphocyte activation Gene-3 (LAG-3) with fibrinogen-like protein 1 (FGL1) in systemic lupus erythematosus [J].
Wang, Bing ;
Zhang, Biqing ;
Wu, Min ;
Xu, Ting .
JOURNAL OF TRANSLATIONAL AUTOIMMUNITY, 2024, 9
[50]   T cell immunoglobulin and mucin-domain containing-3 (TIM-3), lymphocyte-activation gene 3 (LAG-3), and T cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT) - an update on emerging negative immune checkpoints in cancer treatment [J].
Krzyzanowska, Natalia .
ONCOLOGY IN CLINICAL PRACTICE, 2025,